Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON28028
NL-OMON28028
Recruiting
Not Applicable

Clinical Trial to Evaluate Safety and Dose Response Using the C2 CryoBalloon 180 Ablation System for the Treatment of Dysplastic Barrett's Esophagus

C2 Therapeutics, Inc.0 sites25 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBarrett's esophagus<br />Barrett's dysplasia<br />Cryoablation<br />Cryotherapy<br /><br />Barrett slokdarm<br />Barrett neoplasie<br />Cryoablatie<br />Cryotherapie

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Barrett's esophagus<br />Barrett's dysplasia<br />Cryoablation<br />Cryotherapy<br /><br />Barrett slokdarm<br />Barrett neoplasie<br />Cryoablatie<br />Cryotherapie
Sponsor
C2 Therapeutics, Inc.
Enrollment
25
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients with flat\- type BE esophagus, with an indication for ablation therapy, defined as:
  • •\- Diagnosis of LGD or HGD in BE (confirmed by central pathology review), OR

Exclusion Criteria

  • •1\. Esophageal stenosis preventing advancement of a therapeutic endoscope.
  • •2\. Any endoscopically visualized lesion such as ulcers, masses or nodules. Neoplastic nodules must first be treated with ER \>6 weeks prior to planned treatment under this protocol.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Clinical trial to evaluate safety and dose response using the C2 CryoBalloonTM 180 Ablation system for the treatment of dysplastic Barrett*s esophagus
NL-OMON48956C2 Therapeutics, contactpersoon Marcia Wachna25
Not yet recruiting
Phase 2
Clinical Trial of Siddha Medicine Nandhi Mezhugu in the Treatment of Breast CancerHealth Condition 1: C50- Malignant neoplasm of breastHealth Condition 2: C500- Malignant neoplasm of nipple and areolaHealth Condition 3: C500- Malignant neoplasm of nipple and areola
CTRI/2021/10/037630Central Council for Research in Siddha Arumbakkam Chennai
Recruiting
Phase 1
TS-FARMEV StudySolid tumors refractory to oncospecific treatment.
RPCEC00000112Center for Genetic Engineering and Biotechnology (CIGB), in Havana.
Suspended
Phase 1
A study to compare the efficacy of artificial cornea in restoring vision in comparison to human cornea transplant.
CTRI/2014/10/005114Dr May Griffith
Recruiting
Phase 3
Stem cell therapy for COVID-19
IRCT20211012052743N1Cell Gene Medicine Company60